The FDA is using its proposed 2027 budget to lay out policy ideas intended to speed early clinical development in the U.S. and encourage domestic drug manufacturing. FDA Commissioner Marty Makary said the agency needs “giant, big ideas” to counter China’s lead in early-stage clinical execution. Among the proposals: changes aimed at making it easier to initiate first-in-human trials in the U.S., and advantages for U.S.-based generics manufacturers. The initiatives come amid broader political and trade pressure on biopharma supply chains, with domestic production commitments increasingly tied to tariff risk. The budget framework is also being positioned as part of a shift from reactive to proactive regulation, with the agency seeking more predictability for sponsors launching new products. Public discussion around these proposals centers on timeline reductions and whether the reforms can be implemented fast enough for ongoing pipeline programs. For biotech operators, the immediate takeaway is that regulatory strategy is being explicitly linked to industrial policy, not only science review.